Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPRL2 is a gene encoding the nitrogen permease regulator 2-like protein (also known as tumor suppressor candidate 4 or TUSC4), which is a catalytic component of the GATOR1 complex. The GATOR1 complex functions as an inhibitor of the amino acid-sensing branch of the mTORC1 pathway by acting as a GTPase-activating protein for RagA/B within heterodimeric Rag complexes. This inhibition leads to downregulation of mTORC1 signaling in response to amino acid depletion. In cancer research and therapy development, gene therapy using NPRL2 has shown promising preclinical results in inducing anti-tumor immunity—particularly in KRAS/STK11 mutant and anti-PD1 resistant non-small cell lung cancer (NSCLC)—by promoting dendritic cell-mediated antigen presentation and cytotoxic immune cell activation[6][8][10]. Genprex is developing an intravenous formulation using lipid nanoparticles (DOTAP-NPRL2) for systemic delivery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NPRL2.